June Lee
Biotech Executive, Entrepreneur,
Public Company Board Director
June Lee is a physician-scientist with over 20 years in the biotechnology and pharmaceutical industry. Most recently, she was an investor with 5AM Ventures. She has been the Founding CEO for Renasant Bio and Alumis (NASDAQ:ALMS). and CEO o. Previously, she served as Executive Vice President, Chief Development Officer and Chief Operating Officer of MyoKardia where she built and led a world-class development organization that was acquired by Bristol Myers Squibb for $13.1 billion in November 2020. The lead program at MyoKardia, mavacamten, was recently approved by the FDA for use in obstructive hypertrophic cardiomyopathy patients as the first precision therapy in this indication.
Prior to MyoKardia, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator for early-stage technologies. As the therapeutic area head at Genentech, Dr. Lee led early clinical development programs in cardiovascular and metabolic diseases, infectious diseases, and respiratory diseases.
Dr. Lee serves on corporate boards as an independent director for Tenaya Therapeutics, Abivax, Eledon Pharmaceuticals Inc., GenEdit and CinCor (Acquired by Astra Zeneca for $1.8 billion). She also serves as an advisor in the healthcare industry including the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, Stanford’s M-TRAM program, and Neurofibromatosis Therapeutics Acceleration Program at Johns Hopkins. Dr. Lee received her undergraduate degree in chemistry at the Johns Hopkins University, earned her medical degree at the School of Medicine at University of California, Davis, and completed her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.